Sdamlo Solution
Product Images NDC 81279-134

Product Visual Gallery

This gallery contains 9 technical images submitted to the FDA as part of the official labeling for Sdamlo (NDC 81279-134). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Pangea Pharmaceuticals, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Bottle 10mg (Bottle 10mg)

Label for Sdamlo (amlodipine) Oral Solution, 10 mg per bottle, single-dose. The label includes storage instructions (20-25°C), dosage information referencing prescribing details, and directions to reconstitute with water before use. Manufactured for Pangea Pharmaceuticals, LLC, Brielle, NJ. The label displays the NDC 81279-135-10 and states Rx only.*

FDA Label Image

Bottle 2.5mg (Bottle 2.5mg)

The label for Sdamlo (amlodipine) oral solution shows a single-dose bottle format with a strength of 2.5 mg per bottle. It includes storage instructions (20°C to 25°C), directions to reconstitute with water prior to use, and a note to discard after 60 minutes if unused. The label features the Pangea Pharmaceuticals logo and manufacturing location in Brielle, NJ.*

FDA Label Image

Bottle 5mg (Bottle 5mg)

Label for Sdamlo (amlodipine) 5 mg oral solution single-dose bottle by Pangea Pharmaceuticals. The label states 5 mg/bottle strength, includes storage instructions, and advises reconstitution with water prior to use. It also notes the active ingredient as 5 mg amlodipine provided as 6.947 mg amlodipine besylate.*

FDA Label Image

Carton 10mg (Carton 10mg)

Packaging label for Sdamlo (amlodipine) oral solution, 10 mg per bottle. The label indicates the product contains 10 single-dose bottles and instructs to reconstitute with water prior to use. It is labeled by Pangea Pharmaceuticals, LLC, with storage and dosage information visible. The label includes the NDC number 81279-135-10 and directions to keep out of reach of children.*

FDA Label Image

Carton 2.5mg (Carton 2.5mg)

Packaging label for Sdamlo 2.5 mg/bottle oral solution containing amlodipine, labeled for prescription use and manufactured by Pangea Pharmaceuticals, LLC. The package contains 10 single-dose bottles and instructs to reconstitute with water prior to use. Storage and dosage information is partially visible along with a barcode and manufacturer details.*

FDA Label Image

Carton 5mg (Carton 5mg)

Packaging label for Sdamlo (amlodipine) oral solution with a strength of 5 mg per bottle. The label states the product contains 10 single-dose bottles and is manufactured by Pangea Pharmaceuticals, LLC. Instructions indicate the solution must be reconstituted with water prior to use. Storage and dosage information along with safety warnings are also included.*

FDA Label Image

Chemical Structure (Norliquid 01)

Chemical structure of amlodipine, the active ingredient in Sdamlo, an oral solution by Pangea Pharmaceuticals, LLC. The structure depicts the molecular arrangement including aromatic and aliphatic components, chlorine, and methoxy groups as part of the amlodipine molecule.*

FDA Label Image

Figure 1 (Kaplan-Meier Analysis of Composite Clinical Outcomes for Amlodipine versus Placebo)

A line graph comparing event rates over 24 months between placebo and amlodipine groups. The vertical axis shows event rate, and the horizontal axis shows time in months. The graph includes statistical data with a P-value of 0.003, hazard ratio of 0.691, and a 95% confidence interval of 0.54 to 0.88. The number of subjects at risk is displayed along the time axis.*

FDA Label Image

Figure 2 – Effects On Primary Endpoint Of Amlodipine Versus Placebo Across Sub-groups (Norliquid 03)

A forest plot displaying hazard ratios with 95% confidence intervals for subgroups of patients treated with amlodipine versus placebo. Groups include all patients, age categories, gender, baseline sitting systolic blood pressure, baseline vessel disease extent, presence of vessels with >60% stenosis, and PCI-stent stratifications. The x-axis represents hazard ratio values from 0 to 2, with a vertical line at 1 indicating no effect.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.